These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26070015)

  • 1. A Meta-analysis of Sequential Intravenous/Oral Moxifloxacin Monotherapy for Treatment of Skin and Skin Structure Infections.
    Chu Y; Qu J; Qu LY; Luo YF; Jiang MY
    Drug Res (Stuttg); 2015 Dec; 65(12):650-7. PubMed ID: 26070015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.
    Chen F; Zheng N; Wang Y; Wen JL; Tu WF; Du YQ; Lin JM
    Int J Clin Pract; 2013 Sep; 67(9):834-42. PubMed ID: 23952463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
    An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
    Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
    Yuan X; Liang BB; Wang R; Liu YN; Sun CG; Cai Y; Yu XH; Bai N; Zhao TM; Cui JC; Chen LA
    J Chemother; 2012 Oct; 24(5):257-67. PubMed ID: 23182045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
    Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
    Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
    Mu YP; Liu RL; Wang LQ; Deng X; Zhu N; Wei MD; Wang Y
    Int J Clin Pract; 2012 Feb; 66(2):210-7. PubMed ID: 22257046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
    Sun T; Sun L; Wang R; Ren X; Sui DJ; Pu C; Ren Y; Liu Y; Yang Z; Li F
    Chin Med J (Engl); 2014; 127(7):1201-5. PubMed ID: 24709166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin: new preparation. A me-too with more cardiac risks.
    Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Apr; 21(16):5032-8. PubMed ID: 25945019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.
    Zhang L; Wang R; Falagas ME; Chen LA; Liu YN
    Chin Med J (Engl); 2012 Feb; 125(4):687-95. PubMed ID: 22490497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis.
    Zhang YQ; Zou SL; Zhao H; Zhang MM; Han CL
    Am J Emerg Med; 2018 Oct; 36(10):1759-1765. PubMed ID: 29499898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.